[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension].
OBJECTIVE
There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH). The aim of this study was to determinate the effect of MLD on the blood pressure (BP), insulin resistance, and the catecholamine secretion in these patients.


METHODS
Twenty seven patients with TRH from our unit were studied above and after 12 weeks of treatment with MLD (8 mg/day). The following parameters, among others, were analysed: office BP, ambulatory BP (ABPM), rennin, aldosterone and insulin plasmatic levels, urinary catecholamines and the insulin sensitivity index.


RESULTS
Two patients were excluded because of adverse sides. After the treatment period, 53.8% of patients experimented a decrease of office diastolic BP higher than 10 mmHg, and 44% of them presented a decrease of 24-hour diastolic BP higher than 5 mmHg (answer patients). Likewise, 38.5% and 24% of patients achieved an adequate office BP and ABPM control, respectively. Also, a significant decrease of insulin resistance and urinary catecholamines, and an increase of aldosterone in plasma were observed. The rest of parameters remained invariables.


CONCLUSIONS
MLD could be useful in the TRH treatment, because this drug decreased significantly BP, insulin resistance and catecholamine secretion in these patients, with a good tolerance.
Mediavilla García
Juan Diego
JD
Unidad de Hipertensión Arterial y Lípidos, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Sabio
José Mario
JM
Fernández-Torres
Celia
C
Aliaga Martínez
Luis
L
Jiménez-Alonso
Juan
J
D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure; D002395:Catecholamines / Q000652:urine; D017292:Doxazosin / Q000494:pharmacology* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged
D000959:Antihypertensive Agents; D002395:Catecholamines; D000450:Aldosterone; D017292:Doxazosin
Efecto de la doxazosina de liberación modificada en la presión arterial, la resistencia a la insulina y la secreción de catecolaminas en pacientes con hipertensión arterial resistente verdadera.